STOCK TITAN
  1. Home
  2. News
  3. PTCT

PTC Therapeutics Inc - PTCT STOCK NEWS

Welcome to our dedicated news page for PTC Therapeutics (Ticker: PTCT), a resource for investors and traders seeking the latest updates and insights on PTC Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PTC Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PTC Therapeutics's position in the market.

News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PTC Therapeutics, Inc. announced the approval of non-statutory stock options and restricted stock units to six new employees as part of their employment compensation. The awards, made under the Nasdaq inducement grant exception, include 8,090 shares of common stock and 8,290 RSUs. The stock options have an exercise price of $25.32 per share and a 10-year term, vesting over four years. The RSUs also vest over four years, with 25% vesting annually, subject to continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) will host a webcast conference call to report Q1 2024 financial results and provide business updates on April 25. Participants can access the call online or by phone, with a replay available on the company's website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.82%
Tags
conferences earnings
-
News
PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA
Rhea-AI Summary
PTC Therapeutics, Inc. submits the first marketing authorization application for sepiapterin to the European Medicines Agency, with plans for global submissions in 2024. The sepiapterin MAA is for treating pediatric and adult patients with PKU, showing significant reductions in blood phenylalanine levels in clinical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
none
News
PTC Therapeutics Provides Key Regulatory Updates
Rhea-AI Summary
PTC Therapeutics submits BLA for Upstaza™ for AADC deficiency and plans NDA resubmission for Translarna™ based on FDA feedback. Sepiapterin MAA for PKU on track for EMA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none
-
News
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
PTC Therapeutics, Inc. reports a 34% year-over-year growth in total revenue for 2023, with key clinical and regulatory milestones expected in 2024. The company closed 2023 with strong revenue performance, focusing on potential billion-dollar opportunities in various programs. Financially, the company shows positive revenue growth but faces challenges in R&D expenses and losses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.34%
Tags
earnings
-
News
PTC Therapeutics to Participate at Upcoming Investor Conferences
Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) will present a company overview at upcoming conferences, including TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays 26th Annual Healthcare Conference. The presentations will be webcast live on the company's website and archived for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
conferences
News
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) approved non-statutory stock options and restricted stock units for six new employees on Feb. 15, 2024. The awards were granted as part of the new hires' compensation packages. Stock options have an exercise price of $25.69 per share and a 10-year term, while RSUs vest over four years. The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
News
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
PTC Therapeutics, Inc. (PTCT) will host a webcast conference call to report Q4 and full year 2023 financial results and discuss business outlook on Feb. 29, 2024, at 4:30 p.m. EST. Participants can access the call via phone or webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
conferences earnings
-
News
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna™ (ataluren) Following Re-examination Procedure
Rhea-AI Summary
PTC Therapeutics, Inc. received a negative opinion from the CHMP of the EMA regarding the conditional marketing authorization of Translarna™ for nonsense mutation Duchenne Muscular Dystrophy. The decision has disappointed the company and will result in the withdrawal of the therapy for patients in Europe. The CEO expressed concern for the patients and emphasized that the therapy is safe and effective, and that the decision goes against the wishes of the patient community and expert physicians. The European Commission has 67 days to adopt the opinion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
none
News
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) reported unaudited 2023 total revenue of $946 million, showing 35% year-over-year growth. Regulatory filings for sepiapterin in PKU remain on track for 2024, with multiple study readouts planned for 2024, including 12-month interim data from the PIVOT-HD study of PTC518 in HD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.49%
Tags
none
Stock PTCT logo
PTC Therapeutics Inc

Nasdaq:PTCT

PTCT Rankings

#1896 Ranked by Market Cap
#4692 Ranked by Stock Gains
N/A Ranked by Dividends

PTCT Stock Data

2.02B
56.48M
2.79%
112.93%
13.39%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
South Plainfield

About PTCT

ptc is biopharmaceutical company focused on the discovery and development of orally-administered, proprietary small molecule drugs that target post-transcriptional control processes. while ptc’s discovery programs are directed at targets in multiple therapeutic areas, ptc is focusing particularly on the development and commercialization of treatments for orphan and ultra-orphan disorders. post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. ptc’s internally-discovered pipeline addresses multiple therapeutic areas, including neuromuscular disorders, oncology and infectious diseases. for more information on the company, please visit our website www.ptcbio.com.